Poxel pivots to different programs, but questions abound over imeglimin

Poxel has set out a new vision focused on midphase programs in rare metabolic diseases. The new strategy hits pause on plans to start a phase 2b nonalcoholic steatohepatitis (NASH) trial and makes no mention of the next steps for phase 3 ready diabetes drug imeglimin.